George F. Tomossy, David N. Weisstub

Revival

Human Experimentation and Research (2003)

• Gebundenes Buch

Produktbeschreibung

This title was first published in 2003: As new medical technologies and treatments develop with increasing momentum, the legal and ethical implications of research involving human participants are being called into question as never before.

Produktdetails

• Verlag: Routledge
• Seitenzahl: 654
• Erscheinungstermin: 28. Juni 2017
• Englisch
• Abmessung: 240mm x 161mm x 39mm
• Gewicht: 1136g
• ISBN-13: 9781138709607
• ISBN-10: 1138709603
• Artikelnr.: 50154451

Autorenporträt

George F. Tomossy works at Macquarie University, Australia, and David N. Weisstub works within the Faculté de médecine, Université de Montréal, Canada

Inhaltsangabe

Contents: Series preface; Introduction: human research ethics. Part I: The
Historical and Philosophical Foundations: Philosophical reflections on
experimenting with human subjects, Hans Jonas (1969); Experimenting on
human subjects: philosophical perspectives, Ruth Macklin and Susan Sherwin
(2004); Principlism and the ethical appraisal of clinical trials, Eric M.
Meslin, Heather J. Sutherland, James V. Lavery and James E. Till; The
Nuremberg code in light of previous principles and practices in human
experimentation, David J. Rothman; Nuremberg's legacy: some ethical
reflections, James F. Childress; The controversy over retrospective moral
judgment, Allen Buchanan; Looking back and judging our predecessors, Tom L.
Beauchamp; When evil intrudes, Arthur L. Caplan; Shading the truth in
seeking informed consent for research purposes, Sissela Bok; Trust: the
fragile foundation of contemporary biomedical research, Nancy E. Kass,
Jeremy Sugarman, Ruth Faden and Monica Schoch-Spana; Questing for grails:
duplicity, betrayal and self-deception in postmodern medical research,
George J. Annas; Roles and fictions in clinical and research ethics, David
N. Weisstub. Part II: Protecting Human Subjects: Human experimentation and
human rights, Jay Katz; The social control of human biomedical research: an
overview and review of the literature, Paul R. Benson; Goodbye to all that:
the end of moderate protectionism in human subjects research, Jonathan D.
Moreno; Is national, independent oversight needed for the protection of
human subjects?, Alexander Morgan Capron; National, independent oversight:
reinforcing the safety net for human subjects research, Anna C.
Mastroianni; Regulating research for the decisionally impaired:
implications for mental health professionals, Marshall B. Kapp; Are
research ethics bad for our mental health?, Robert Michels; The reform of
adult guardianship laws: the case of non-therapeutic experimentation;
George F. Tomossy and David N. Weisstub. Part III: Risk and Responsibility:
The ethical analysis of risk, Charles Weijer; Defining and describing
benefit appropriately in clinical trials, Nancy M.P. King; What research
with stored samples teaches us about research with human subjects, David
Wendler; Uncertainty in clinical research; Robert J. Levine; Equipoise and
the ethics of clinical research, Benjamin Freedman; Equipoise, knowledge
and ethics in clinical research and practice, Richard Ashcroft; Ethical
considerations concerning treatment allocation in drug development trials,
S. Senn; When are placebo-controlled trials no longer appropriate?, Baruch
A. Brody. Part IV: Globalization and Corporation - Trust and Participation:
International research: ethical imperialism or ethical pluralism?, Ruth
Macklin; Is academic medicine for sale?, Marcia Angell; Ethical issues in
research relationships between universities and industry, James T. Rule and
Adil E. Shamoo; Uneasy alliance - clinical investigators and the
pharmaceutical industry, Thomas Bodenheimer; Ethics review for sale?
Conflict of interest and commercial research review boards, Trudo Lemmens
and Benjamin Freedman; Dealing with conflicts of interest in biomedical
research: IRB oversight as the next best solution to the abolitionist
approach, Jesse A. Goldner; Restoring and preserving trust in biomedical
research, Mark Yarborough and Richard R. Sharp; Privatized biomedical
research, public fears, and the hazards of government regulation: lessons
from stem cell research, David B. Resnik; Name index.